BACKGROUND:Systemic thromboembolism and bleeding remain the two most common and serious complications of catheter ablation of atrial fibrillation. A variety of periprocedure anticoagulation strategies have been proposed to mitigate these risks. Although operators are now routinely administering dabigatran for anticoagulation in this setting, its relative safety and effectiveness compared to warfarin are unknown. METHODS AND RESULTS: A total of 202 patients receiveddabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation. A comparison group of 202 patients treated withwarfarin was randomly selected from patients undergoing atrial fibrillation (AF) ablation during the same time period. AF types were paroxysmal in 223 patients, persistent in 158 patients, and longstanding persistent in 13 patients. Mean age was 60.0 ± 10.5 years, 55 % had a history of hypertension, and mean CHADS-VASc score was 1.7 ± 1.3. "Continuous" warfarin or dabigatran was administered in 80 and 32 % of patients, respectively. Time to first dose of dabigatran post-procedure was 12.2 ± 10.3 h. Two dabigatran and no warfarin-treated patients had systemic thromboembolism (p = NS); five dabigatran and three warfarin-treated patients had bleeding complications (p = NS, combined endpoint p = 0.116). One dabigatran patient had severe pericardial bleeding (3 L blood loss). CONCLUSIONS: In a retrospective pilot trial comparing the risks of systemic thromboembolism or bleeding complications in patients treated withwarfarin or dabigatran anticoagulation, the outcomes were similar. A prospective trial is warranted.
RCT Entities:
BACKGROUND:Systemic thromboembolism and bleeding remain the two most common and serious complications of catheter ablation of atrial fibrillation. A variety of periprocedure anticoagulation strategies have been proposed to mitigate these risks. Although operators are now routinely administering dabigatran for anticoagulation in this setting, its relative safety and effectiveness compared to warfarin are unknown. METHODS AND RESULTS: A total of 202 patients received dabigatran as part of their periprocedural anticoagulation regimen at the time of initial or redo catheter ablation for symptomatic atrial fibrillation. A comparison group of 202 patients treated with warfarin was randomly selected from patients undergoing atrial fibrillation (AF) ablation during the same time period. AF types were paroxysmal in 223 patients, persistent in 158 patients, and longstanding persistent in 13 patients. Mean age was 60.0 ± 10.5 years, 55 % had a history of hypertension, and mean CHADS-VASc score was 1.7 ± 1.3. "Continuous" warfarin or dabigatran was administered in 80 and 32 % of patients, respectively. Time to first dose of dabigatran post-procedure was 12.2 ± 10.3 h. Two dabigatran and no warfarin-treated patients had systemic thromboembolism (p = NS); five dabigatran and three warfarin-treated patients had bleeding complications (p = NS, combined endpoint p = 0.116). One dabigatranpatient had severe pericardial bleeding (3 L blood loss). CONCLUSIONS: In a retrospective pilot trial comparing the risks of systemic thromboembolism or bleeding complications in patients treated with warfarin or dabigatran anticoagulation, the outcomes were similar. A prospective trial is warranted.
Authors: Antonio Sorgente; Gian-Battista Chierchia; Carlo de Asmundis; Andrea Sarkozy; Lucio Capulzini; Pedro Brugada Journal: Europace Date: 2011-07-21 Impact factor: 5.214
Authors: R A Grimm; W J Stewart; J D Maloney; G I Cohen; G L Pearce; E E Salcedo; A L Klein Journal: J Am Coll Cardiol Date: 1993-11-01 Impact factor: 24.094
Authors: Hakan Oral; Aman Chugh; Mehmet Ozaydin; Eric Good; Jackie Fortino; Sundar Sankaran; Scott Reich; Petar Igic; Darryl Elmouchi; David Tschopp; Alan Wimmer; Sujoya Dey; Thomas Crawford; Frank Pelosi; Krit Jongnarangsin; Frank Bogun; Fred Morady Journal: Circulation Date: 2006-08-14 Impact factor: 29.690
Authors: Oussama M Wazni; Salwa Beheiry; Tamer Fahmy; Conor Barrett; Steven Hao; Dimpi Patel; Luigi Di Biase; David O Martin; Mohamed Kanj; Mauricio Arruda; Jennifer Cummings; Robert Schweikert; Walid Saliba; Andrea Natale Journal: Circulation Date: 2007-11-12 Impact factor: 29.690
Authors: Daniel Scherr; Kavita Sharma; Darshan Dalal; David Spragg; Karuna Chilukuri; Alan Cheng; Jun Dong; Charles A Henrikson; Saman Nazarian; Ronald D Berger; Hugh Calkins; Joseph E Marine Journal: J Cardiovasc Electrophysiol Date: 2009-12
Authors: Benjamin A Steinberg; Vic Hasselblad; Brett D Atwater; Tristram D Bahnson; Jeffrey B Washam; John H Alexander; James P Daubert; Jonathan P Piccini Journal: J Interv Card Electrophysiol Date: 2013-07-24 Impact factor: 1.900
Authors: Aysha Arshad; Christopher K Johnson; Suneet Mittal; Eric Buch; Ismail Hamam; Thanh Tran; Richard E Shaw; Dan Musat; Mark Preminger; Tina Sichrovsky; Bengt Herweg; Kalyanam Shivkumar; John Hummel; Jonathan S Steinberg Journal: Pacing Clin Electrophysiol Date: 2014-05-04 Impact factor: 1.976
Authors: Jerry J Flores; Yang Zhang; Damon W Klebe; Tim Lekic; Weiling Fu; John H Zhang Journal: Expert Opin Pharmacother Date: 2014-02-04 Impact factor: 3.889
Authors: Luis I Garcia Md; Mark A Mascarenhas Md; Kartikya Ahuja Md; Anthony Aizer Md; Neil Bernstein Md; Scott A Bernstein Md; Steve J Fowler Md; Douglas S Holmes Md; David S Park Md And; Larry Chinitz Md Journal: J Atr Fibrillation Date: 2014-02-28